78 related articles for article (PubMed ID: 18303603)
1. ["... and now about the costs!"].
Rohde D
Aktuelle Urol; 2008 Jan; 39(1):2 p preceding table of contents. PubMed ID: 18303603
[No Abstract] [Full Text] [Related]
2. The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal.
Barata PC; Alpuim Costa D; Passos Coelho JL; Da Luz R
Acta Med Port; 2018 Aug; 31(7-8):373-375. PubMed ID: 30189164
[No Abstract] [Full Text] [Related]
3. Advanced renal cell carcinoma in Australia, 2015: what should we do?
Davis ID
Asia Pac J Clin Oncol; 2014 Dec; 10(4):285-8. PubMed ID: 25392943
[No Abstract] [Full Text] [Related]
4. The Authors Respond.
Hansen RN; Hackshaw MD; Sullivan SD; Ramsey SD
J Manag Care Spec Pharm; 2015 Sep; 21(9):844. PubMed ID: 26536677
[No Abstract] [Full Text] [Related]
5. Welcome clinical leadership at NICE.
Lancet; 2008 Aug; 372(9639):601. PubMed ID: 18722845
[No Abstract] [Full Text] [Related]
6. Treatment patterns and costs for metastatic renal cell carcinoma patients with private insurance in the United States.
Geynisman DM; Hu JC; Liu L; Tina Shih YC
Clin Genitourin Cancer; 2015 Apr; 13(2):e93-100. PubMed ID: 25450038
[TBL] [Abstract][Full Text] [Related]
7. The Authors Respond.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; El Khoury MH
J Manag Care Spec Pharm; 2015 Sep; 21(9):836-40. PubMed ID: 26536676
[No Abstract] [Full Text] [Related]
8. The National Institute of Health and Clinical Excellence rejects new treatments for renal cell cancer: Cinderella's invitation is cancelled.
Eisen T
BJU Int; 2008 Dec; 102(11):1491-2. PubMed ID: 19007367
[No Abstract] [Full Text] [Related]
9. [Ⅳ. Current Economic Issues in Treatment for Metastatic Renal Cell Carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2019 Jan; 46(1):50-53. PubMed ID: 30765642
[No Abstract] [Full Text] [Related]
10. The role of socioeconomic status in renal cell carcinoma.
Hellenthal NJ; Bermejo CE
Urol Oncol; 2012; 30(1):89-94. PubMed ID: 21908209
[TBL] [Abstract][Full Text] [Related]
11. We have a new treatment, but you can't afford it.
Desch CE
J Natl Compr Canc Netw; 2006 Sep; 4(8):720-3. PubMed ID: 16995283
[No Abstract] [Full Text] [Related]
12. Sequential therapies in metastatic renal cell carcinoma: option or strategy?
Bracarda S; De Simone V
Eur Urol; 2008 Dec; 54(6):1219-20; discussion 1221-2. PubMed ID: 18778889
[No Abstract] [Full Text] [Related]
13. Health economics: Life in the balance.
Cressey D
Nature; 2009 Sep; 461(7262):336-9. PubMed ID: 19759594
[No Abstract] [Full Text] [Related]
14. [Cancer of the kidney in adults. Economic aspects].
Prog Urol; 1997 Nov; 7(5):901-4. PubMed ID: 9458486
[No Abstract] [Full Text] [Related]
15. FDA grants orphan-drug status to Aeterna's Neovastat for kidney cancer.
Expert Rev Anticancer Ther; 2002 Dec; 2(6):618. PubMed ID: 12503200
[No Abstract] [Full Text] [Related]
16. Update on the use of mTOR inhibitors in renal cell carcinoma.
Rini BI
Clin Adv Hematol Oncol; 2008 Oct; 6(10):722-4. PubMed ID: 18997660
[No Abstract] [Full Text] [Related]
17. The new medical treatment of metastatic renal cell carcinoma: a good debut, a lot of open questions.
Ficarra V; Novara G
Eur Urol; 2008 Aug; 54(2):252-5. PubMed ID: 18513851
[No Abstract] [Full Text] [Related]
18. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
Ficarra V; Novara G
Eur Urol; 2008 Aug; 54(2):324-5. PubMed ID: 18485580
[No Abstract] [Full Text] [Related]
19. Editorial comment on: update on the medical treatment of metastatic renal cell carcinoma.
Van Poppel H
Eur Urol; 2008 Aug; 54(2):324. PubMed ID: 18485572
[No Abstract] [Full Text] [Related]
20. New mTOR inhibitor for renal cell cancer.
Wilkes GM
Oncology (Williston Park); 2009 Jul; 23(8 Suppl):54-6. PubMed ID: 19860046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
